

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****INFORMATION DISCLOSURE  
STATEMENT (PTO 1449)**

ATTORNEY DOCKET NO.

**70078.0020USWO**

U.S. APPLICATION SERIAL NO.

**New**

CONFIRMATION NO.

**New**

FILING DATE

**Herewith**

INVENTOR(S)

**Renato MONTEIRO et al.**

EXAMINER

**New**

GROUP ART UNIT

**New**

TITLE OF APPLICATION

**MONOVALENT LIGAND OF THE Fc $\alpha$ RI RECEPTOR AS AN ANTI-INFLAMMATORY AGENT****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/MS/	A	6,018,031	01/25/2000	Shen et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/MS/	B	99/41285	08/19/1999	WIPO				
	C	02/064634	08/22/2002	WIPO				
/MS/	D	99/28349	06/10/1999	WIPO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/MS/	E	MORTON, H Craig et al., "CD89: the Human Myeloid IgA Fc Receptor," ARCHIVUM IMMUNOLGIAE ET THERAPIAE EXPERIMENTALIS, vol. 49, no. 3, 2001, pages 217-229, XP009035083, PL ISSN: 0004-069X
/MS/	F	PCT International Search Report dated June 6, 2006
	G	
	H	
	I	
	J	
	K	
	L	
	M	
	N	
	O	
	P	
	Q	
	R	

EXAMINER

**/Michael Szperka/**

DATE CONSIDERED

**01/27/2010**

EXAMINER: Initial if the reference is considered, whether or not the citation is in conformance with MPEP 609. Draw a line through the citation if it is not in conformance and it is not considered. Include a copy of this form with the next communication to the Applicant.